AVAILABLE OPTIONS FOR HCV INFECTION TREATMENT IN DECOMPENSATED LIVER CIRRHOSIS PATIENTS
DOI: 10.22138/2500-0918-2023-20-3-79-91
M.A. Anashkina¹, E.N. Bessonova¹, V.V. Bazarnyi², N.F. Klimusheva¹
¹ State Autonomous Health Care Institution «Sverdlovsk Regional Clinical Hospital №1»
Yekaterinburg, Russian Federation;
² Federal State Budgetary Educational Institution of Higher Education Ural State Medical University of the Ministry of Health of the Russian Federation, Yekaterinburg, Russian Federation
Abstract. Introduction. Chronic viral hepatitis C is an infectious disease that is widespread among the working-age population and is often diagnosed at liver cirrhosis stage. The opportunity to slow down the progress of infection and subsequent complications appeared when the drugs with direct antiviral action became wildly available. However, the problem of antiviral treatment decompensated liver cirrhosis patients (Child-Pugh classes B and C) is still controversial and discussed. This category of patients is still the most difficult to treat. Research objectives. Search for a comprehension of the optimal liver function for the safe administration of DAA, determination of the optimal timing and DAA regimen for patients with decompensated cirrhosis based on a review of the literature. Methods. The source of information was PubMed medical bibliographic databases, from which 26 original articles for 2015–2021 were selected. Conclusion. Relatively small number of patients with cirrhosis Child-Pugh C, the high incidence of adverse events and decompensations, and the absence of clearly defined criteria for prescribing DAA, this problem requires further study and research.
Keywords: viral hepatitis C, decompensated liver cirrhosis, antiviral therapy, waiting list for liver transplantation
REFERENCES:
1. Clinical guideline «Chronic viral hepatitis HCV» 2021 г. Russian Ministry of Health.
2. https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-c
3. Francesco Negro, Nina Weis and Jeffrey Lazarus, EASL policy statement Hepatitis C Elimination, June 2019.
4. Ivashkin V.T., Maevskaja M.V., Zharkova M.S., Zhigalova S.B., Kicenko E.A., Manuk’jan G.V., Truhmanov A.S., Maev I.V., Tihonov I.N., Deeva T.A. Klinicheskie rekomendacii Rossijskogo obshhestva po izucheniju pecheni i Rossijskoj gastrojenterologicheskoj associacii po diagnostike i lecheniju fibroza i cirroza pecheni i ih oslozhnenij. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii.. 2021;31(6):56–102. doi.org/10.22416/13824376-2021-31-6-56-102
5. National medical recommendations: Liver transplantation, Professional setting: All-Russian public organization of transplantologists «Russian Transplant Society», 2016.
6. The European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol (2018), https://doi.org/10.1016/j.jhep.2018.03.024
7. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C | © 2014-2022 AASLD and IDSA v2022.1
8. Forman, L. M., J. D. Lewis, J. A. Berlin, H. I. Feldman, M. R. Lucey The association between hepatitis C infection and survival after orthotopic liver transplantation / Forman, L. M., J. D. Lewis, J. A. Berlin, H. I. Feldman, M. R. Lucey //Gastroenterology. – 2002. – No 122 – 4 – P. 889-96.
9. «Serious Liver Injury Tied to HCV Drugs in Rare Cases, FDA Warns», Rabia S. Tuma, Medscape.
10. Practice guideline: EASL recommendations on treatment of hepatitis C: Final update of the series//J. Hepatol. – 2020 – P. 1170 – 1218.
11. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr. et al., SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep;149 (3):649-59. doi: 10.1053/j.gastro.2015.05.010. Epub 2015 May 15. PMID: 25985734.
12. Cheung, M. C.M. et al. (2016) Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 65(4), pp. 741-747. doi:10.1016/j.jhep.2016.06.019
13. Jacobson IM, Poordad F, Firpi-Morell R, Firpi-Morell R. Elbasvir/grazoprevir in people with hepatitis C genotype 1 infection and Child-Pugh class B cirrhosis: the C-SALT study. Clin Transl Gastroenterol. 2019;10(4):e00007.
14. Instructions for the medical use of the drug Zepatir, approved by the Ministry of Health of the Russian Federation, State Register of Medicines.
15. Instructions for the medical use of the drug Vikeyra Pak, approved by the Ministry of Health of the Russian Federation, State Register of Medicines.
16. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S et al., European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol. 2016 Sep;65(3):524-31. doi: 10.1016/j.jhep.2016.05.010. Epub 2016 May 17. PMID: 27212241.
14. Dhanasekaran, R. and Kwo, P.Y. (2021), Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat. Clinical Liver Disease, 17: 169-173. https://doi.org/10.1002/cld.1003
15. Foster GR, McLauchlan J, Irving W, et al. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol. 2015;62(Suppl 2):S190–S191.
16. Di Maira T, Torregrosa A, Navarro V, Sánchez D, Fornés V, Berenguer M. Liver Volume as a Predictor of Functional Improvement Post-DAA Treatment. Transplantation. 2018 Feb;102(2):e74-e81. doi: 10.1097/TP.0000000000001990. PMID: 29087972.
17. Fernandez-Carrillo C, Lens S, Llop E, Pascasio JM, Fernandez I, Baliellas C et al. Treatment of hepatitis C virus in patients with advanced cirrhosis: always justified? Analysis of the HEPA-C registry. J. Hepatol. 2016;64(Suppl. 2):S133. 1810-1822. doi: 10.1002/hep.29097. Epub 2017 Apr 28. PMID: 28170112.
18. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM et al.; ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31;373(27):2618-28. doi: 10.1056/NEJMoa1512614. Epub 2015 Nov 16. PMID: 26569658.
Authtors
Maria A. Anashkina
State Autonomous Health Care Institution «Sverdlovsk Regional Clinical Hospital №1»
Gastrornterologist of the gastroenterology department
Anashkina.gastro.ekb@gmail.com
Yekaterinburg, Russian Federation
Elena N. Bessonova
State Autonomous Health Care Institution «Sverdlovsk Regional Clinical Hospital №1»
MD, PhD, head of gastroenterology department
bess.elena@bk.ru
Yekaterinburg, Russian Federation
Vladimir V. Bazarnyi
Federal State Budgetary Educational Institution of Higher Education Ural State Medical University of the Ministry of Health of the Russian Federation
MD, PhD, Professor of the Department of clinical laboratory diagnostics and bacteriology
vlad-bazarny@yandex.ru
Yekaterinburg, Russian Federation
Natalia F. Klimusheva
State Autonomous Health Care Institution «Sverdlovsk Regional Clinical Hospital №1»
MD, PhD, Deputy Director for Clinical Care
klimusheva@mis66.ru
Yekaterinburg, Russian Federation